Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Reduktion af blodrecirkulation i veno-venøs ECMO

13. november 2026 opdateret af: Steffen Weber-Carstens, Charite University, Berlin, Germany

Reduktion af blodrecirkulation i veno-venøs ECMO gennem ultralydsfortyndingsmålinger (ECMO Circulation Study)

Blood which recirculates through the circuit of a veno-venous Extracorporeal Membrane Oxygenation (V-V ECMO) does not contribute to the systemic oxygenation of a patient on V-V ECMO and is called the recirculation fraction (Rf). Theoretically, the optimization of ECMO blood flow is possible using Rf measurements.

A prospective, observational study will be performed measuring the Rf of total ECMO blood flow in patients with acute respiratory distress syndrome (ARDS) on V-V ECMO with an ultrasound dilution technique.

ECMO blood flow will be optimized by reducing ECMO blood flow in accordance with the measured Rf as long as systemic oxygenation is not compromised.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

Based on data from the 'Blood Recirculation and vvECMO' trial (ClinicalTrials.gov ID: NCT03200314) (i.e. an expected frequency of successful blood flow reduction of 66.7%), using a one-sample Chi square test, a two-sided type-1 error of 5%, a power of 80%, a total of 68 patients is needed to show that the proportion of patients with a secure ECMO blood flow reduction is greater than 50%. Presumably, 136 Patients have to be included into the trial to study 68 patients with a relevant Rf since not all patients on V-V ECMO suffer from a high Rf.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

77

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • State of Berlin
      • Berlin, State of Berlin, Tyskland, 13353
        • Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

Inclusion Criteria:

  • patients aged 18 years or older
  • ARDS
  • veno-venous ECMO

Exclusion Criteria:

  • age < 18 years
  • hemodynamic instability during measurement of recirculation
  • pregnancy
  • inability to obtain patient's consent or consent of legal guardian

Beskrivelse

Patients aged 18 years or older requiring veno-venous ECMO for treatment of refractory hypoxemia in ARDS.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Successful ECMO blood flow reduction
Tidsramme: Once within the first week after initiation of ECMO therapy

Number of patients with a relevant recirculation fraction and successful ECMO blood flow reduction

Once within the first week after initiation of ECMO therapy

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Recirculation fraction
Tidsramme: Once within the first week after initiation of ECMO therapy

Fraction of blood recirculating through the ECMO circuit

Once within the first week after initiation of ECMO therapy
Arterial blood oxygen content
Tidsramme: Once within the first week after initiation of ECMO therapy

Arterial blood oxygen content before vs. after reduction of ECMO blood flow

Once within the first week after initiation of ECMO therapy
Extracorporeal blood Flow
Tidsramme: Once within the first week after initiation of ECMO therapy

ECMO Blood Flow before vs. after reduction of ECMO blood flow

Once within the first week after initiation of ECMO therapy
Extracorporeal gas flow
Tidsramme: Once within the first week after initiation of ECMO therapy

ECMO Sweep Gas flow

Once within the first week after initiation of ECMO therapy
Length of ECMO therapy
Tidsramme: Daily until the end of ECMO therapy (approximately 14 days)

Days on ECMO

Daily until the end of ECMO therapy (approximately 14 days)
Cannula position and distance
Tidsramme: Once within the first week after initiation of ECMO therapy

The distance between the tip of drainage and return cannula will be measured in the existing medical imaging (e.g. CT scans)

Once within the first week after initiation of ECMO therapy
Right heart dysfunction
Tidsramme: Once within the first week after initiation of ECMO therapy

Existing echocardiography will be evaluated for possible right heart dysfunction

Once within the first week after initiation of ECMO therapy
Length of mechanical ventilation
Tidsramme: Entire duration of the ICU stay (approximately 28 days)

Length of mechanical ventilation

Entire duration of the ICU stay (approximately 28 days)
Complications of ECMO therapy
Tidsramme: Length of ECMO therapy (approximately 14 days)

Incidence of cannula or system changes (i.e. due to circuit clotting), complications attributed to ECMO therapy like bleeding complications from the cannulation site, transfusion requirements, hemolysis

Length of ECMO therapy (approximately 14 days)
ICU mortality
Tidsramme: Entire duration of the ICU stay (approximately 28 days)

ICU mortality

Entire duration of the ICU stay (approximately 28 days)
ICU length of stay
Tidsramme: Entire duration of the ICU stay (approximately 28 days)

ICU length of stay

Entire duration of the ICU stay (approximately 28 days)
Incidence of ICU-acquired organ dysfunctions and complications
Tidsramme: Entire duration of the ICU stay (approximately 28 days)

Cerebral-, cardiovascular-, cardiac- pulmonary-, gastrointestinal- and renal dysfunctions, ICU-acquired infections

Entire duration of the ICU stay (approximately 28 days)
ECMO blood flow over time
Tidsramme: Daily until the end of ECMO therapy (approximately 14 days)

ECMO blood and sweep gas flow over time

Daily until the end of ECMO therapy (approximately 14 days)
ECMO sweep gas flow over time
Tidsramme: Daily until the end of ECMO therapy (approximately 14 days)

ECMO sweep gas flow over time

Daily until the end of ECMO therapy (approximately 14 days)
Mobility at ICU discharge
Tidsramme: Discharge from the ICU (approximately 28 days)

Level of mobility the patient has reached at ICU discharge (recumbent, sitting, standing, walking with help, walking independently)

Discharge from the ICU (approximately 28 days)
Weaning level at ICU discharge
Tidsramme: Discharge from the ICU (approximately 28 days)

Level of weaning reached at ICU discharge

Discharge from the ICU (approximately 28 days)
Status of mechanical ventilation at ICU discharge
Tidsramme: Discharge from the ICU (approximately 28 days)

Status of mechanical ventilation at ICU discharge including all relevant settings and parameters

Discharge from the ICU (approximately 28 days)
Level of organ dysfunction at ICU discharge
Tidsramme: Discharge from the ICU (approximately 28 days)

Sepsis-related Organ Failure Assessment Score at ICU discharge

Discharge from the ICU (approximately 28 days)
Level of consciousness at ICU discharge
Tidsramme: Discharge from the ICU (approximately 28 days)

Glasgow Coma Scale at ICU discharge

Discharge from the ICU (approximately 28 days)
Level of disease severity
Tidsramme: Discharge from the ICU (approximately 28 days)

Acute Physiology And Chronic Health Evaluation at ICU discharge

Discharge from the ICU (approximately 28 days)
Hospital acquired infections related to ECMO therapy
Tidsramme: Entire duration of ECMO therapy

Infection/colonisation of the ECMO circuit

Entire duration of ECMO therapy
Bleeding and thrombembolic complications of ECMO therapy
Tidsramme: Entire duration of ECMO therapy

Bleeding complications, thrombembolic events, overall use of blood products and coagulation factors, electron microscopic evaluation of selected membranes after change or weaning of the ECMO circuit

Entire duration of ECMO therapy

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Martin Russ, Dr. med., Charite University Hospital Berlin
  • Ledende efterforsker: Philipp A Pickerodt, Dr. med., Charite University Hospital Berlin
  • Ledende efterforsker: Vladimir Skrypnikov, Dr. med., Charite University Hospital Berlin
  • Ledende efterforsker: Steffen Weber-Carstens, Prof. Dr. med., Charite University Hospital Berlin

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

20. november 2020

Primær færdiggørelse (Faktiske)

5. maj 2026

Studieafslutning (Faktiske)

5. maj 2026

Datoer for studieregistrering

Først indsendt

14. september 2020

Først indsendt, der opfyldte QC-kriterier

12. februar 2021

Først opslået (Faktiske)

15. februar 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • EA115620

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .